Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New inhaled TB drug shows promise in early trial

NCT ID NCT07073638

Disease control Sponsor: Thirty Respiratory Limited Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new inhaled medicine called RESP30TB in 24 adults with newly diagnosed, drug-sensitive tuberculosis of the lungs. The main goals are to see if the drug is safe and how well it kills TB bacteria in the early days of treatment. Participants will inhale the drug and be closely monitored for side effects and sputum changes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 24 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2025

Expected to finish

Nov 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Provide written, informed consent prior to all trial-related procedures and agree to undergo all trial procedures. 2. Body weight (in light clothing and with no shoes) between 40 and 90 kg, inclusive. 3. Newly diagnosed pulmonary TB. 4. Rifampicin susceptible pulmonary TB as determined by molecular testing. 5. Ability to produce an adequate volume of sputum as estimated from a pre-treatment overnight sputum collection sample (estimated 10 mL or more). 6. Spirometry performed during screening with a Forced Expiration Volume in the first second (FEV1) of ≥ 40%. 7. Be of non-childbearing potential or willing to use effective methods of contraception, as defined in section 4.3.4. Exclusion Criteria: 1. HIV positive AND CD4 \< 350 cells/mm3 OR are receiving antiviral therapy (ART) 2. Baseline Methaemoglobin saturation (SpMet) \>3%. 3. Female patients who is pregnant or breast-feeding. 4. Patients planning to conceive a child within the anticipated period of trial participation and for at least 90 days after the last dose of IMP in the trial. 5. Participation in other clinical studies with investigational agents within 8 weeks prior to screening. 6. Treatment received for this episode of TB with any drug active against M.tb 7. Treatment with immunosuppressive medications such as TNF-alpha inhibitors within 2 weeks prior to screening, or systemic corticosteroids for more than 7 days within 2 weeks prior to screening. 8. Treatment with NO and other NO donor agents, phosphodiesterase inhibitors and lung surfactant drugs, within 30 days prior to screening.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Pulmonary tuberculoses are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

pulmonary tuberculosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Pulmonary tuberculoses

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • TASK Clinical Research Centre

    RECRUITING

    Cape Town, Bellville, 7531, South Africa

More trials for these conditions

Other studies related to the condition(s) this trial covers.